These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25751270)

  • 21. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
    Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
    J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
    Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Paish EC; Macmillan RD; Ellis IO; Green AR
    Breast Cancer Res Treat; 2010 Jul; 122(1):45-53. PubMed ID: 19701705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
    Heikkinen T; Korpela T; Fagerholm R; Khan S; Aittomäki K; Heikkilä P; Blomqvist C; Carpén O; Nevanlinna H
    Breast Cancer Res Treat; 2013 Aug; 141(1):79-88. PubMed ID: 23974830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.
    Hilvo M; Denkert C; Lehtinen L; Müller B; Brockmöller S; Seppänen-Laakso T; Budczies J; Bucher E; Yetukuri L; Castillo S; Berg E; Nygren H; Sysi-Aho M; Griffin JL; Fiehn O; Loibl S; Richter-Ehrenstein C; Radke C; Hyötyläinen T; Kallioniemi O; Iljin K; Oresic M
    Cancer Res; 2011 May; 71(9):3236-45. PubMed ID: 21415164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
    Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
    Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
    Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
    Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COX2 overexpression is a prognostic marker for Stage III breast cancer.
    Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
    Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer.
    Chen HW; Du CW; Wei XL; Khoo US; Zhang GJ
    Curr Mol Med; 2013 Mar; 13(3):410-6. PubMed ID: 23331013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
    Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
    Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer.
    Yakirevich E; Samkari A; Holloway MP; Lu S; Singh K; Yu J; Fenton MA; Altura RA
    Hum Pathol; 2012 Jun; 43(6):865-73. PubMed ID: 22055399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer.
    Park SY; Kim HM; Koo JS
    Breast Cancer Res Treat; 2015 Feb; 149(3):727-41. PubMed ID: 25667103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
    Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
    Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
    Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
    Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.